Statin initiation in dialysis patients: The hardship of non-prescription

Atherosclerosis. 2021 Nov:337:53-56. doi: 10.1016/j.atherosclerosis.2021.10.004. Epub 2021 Oct 13.

Authors

Manfred Hecking¹, Angelo Karaboyas², Gerit-Holger Schernthaner³, Christoph Wanner⁴

Affiliations

¹ Department of Internal Medicine III, Clinical Division of Nephrology & Dialysis, Medical University of Vienna, Austria.
² Arbor Research Collaborative for Health, Ann Arbor, MI, USA.
³ Department of Internal Medicine II, Clinical Division of Angiology, Medical University of Vienna, Austria. Electronic address: gerit.schernthaner@meduniwien.ac.at.
⁴ Department of Medicine I, Division of Nephrology, Universitätsklinik Würzburg, Germany.

PMID: 34663493
DOI: 10.1016/j.atherosclerosis.2021.10.004

No abstract available

Keywords: Dialysis; Lipid management; Outcomes.

Publication types

Editorial

MeSH terms

Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Renal Dialysis
Retrospective Studies

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors